Clinical trials: Solid Tumors (Phase 1)
Advanced Malignant Solid Tumors
A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor
This study is an open-label, multicenter, dose-escalation and dose-expansion Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of AK150…
- Trial name
- NCT07566247
- Testing
- AK150
- Where
- 3 sites in China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Akeso
Cancer, Neoplasm
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
The study enrolled advanced cancer participants with unresectable or metastatic disease who were refractory to or were not candidates for standard approved therapy.
- Trial name
- NCT04717375
- Testing
- SAR444881, Pembrolizumab, Cetuximab
- Where
- 18 sites in United States, Canada and 2 more
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Sanofi
Unspecified Adult Solid Tumor, Protocol Specific
Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Healthy Men
This randomized phase I trial is studying the side effects and best dose of Bowman-Birk inhibitor concentrate in preventing cancer in healthy men.
- Trial name
- NCT00287833
- Testing
- Bowman-Birk inhibitor concentrate
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor
To Evaluate the Safety, Pharmacokinetic and the Effect of Food After Administration of ABN401 in Healthy Adult Volunteers
This randomized open-label, two-way crossover study is designed to evaluate the safety and pharmacokinetic characteristics of ABN401, and the effect of high-fat meal on the pharmacokinetic profiles of ABN401 and its metabolites…
- Trial name
- NCT05248074
- Testing
- High-fat meal (over 900 kcal), ABN401 (investigational product)
- Where
- South Korea
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Abion Inc
Solid Tumors Harboring NTRK Fusion
Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants
In this study, the researchers will compare 2 new tablet forms of BAY2731954 with liquid oral forms of BAY2731954. A maximum of 61 healthy volunteers aged 18 to 55 will be asked to participate. The study will have 2 parts.
- Trial name
- NCT04771390
- Testing
- Selitrectinib (BAY2731954) Adult tablet, Selitrectinib (BAY2731954) Pediatric tablet, Selitrectinib (BAY2731954) Oral solution
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Bayer
Unspecified Adult Solid Tumor, Protocol Specific
UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of resveratrol may prevent cancer.
- Trial name
- IRB 2004-535 (NCT00098969)
- Testing
- resveratrol
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias
Background: Bone marrow stem cells, which are found in the bone marrow and blood stream, can be collected and transplanted to treat a variety of types of cancer in a process known as hematopoietic stem cell transplantation…
- Trial name
- NCT01287104
- Testing
- Natural Killer (NK) Cell Infusion, Stem Cell Infusion
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Adult
Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects
This is an open-label, non-randomized, clinical study to evaluate the drug interaction between itraconazole, rifampin or Cocktail and JMKX001899 in healthy subjects.
- Trial name
- NCT06348290
- Testing
- JMKX001899, Itraconazole, Midazolam
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Jemincare
Brain and Central Nervous System Tumors, Leukemia
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial
RATIONALE: Gathering information about why patients or their guardians agree or decline to participate in the optional pharmacokinetic portion of a phase I treatment study may help doctors plan clinical trials in the future.
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00890435
- Testing
- questionnaire administration, psychosocial assessment and care
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Children's Oncology Group
Solid Tumours
To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
Study to assess the effect of Rifampicin on the pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
- Trial name
- NCT02046850
- Testing
- selumetinib, rifampicin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Small Cell Lung Cancer, Solid Tumors
A Study of AL8326 in Healthy Subjects
This experiment plans to enroll 6-8 healthy male subjects in China, and ultimately collect complete test samples and data from at least 6 subjects as the standard.
- Trial name
- NCT07132957
- Testing
- 14C-labeled AL8326
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Advenchen Laboratories Nanjing Ltd.
Advanced Solid Tumors
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers
This is a double blind Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of DN1406131, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme…
- Trial name
- NCT03641794
- Testing
- DN1406131
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Solid Tumours
To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
Study to assess the effect of food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
- Trial name
- NCT01974349
- Testing
- selumetinib (oral)
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Patients With Solid Tumors
A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors
The study is being conducted to evaluate the safety, radiation dosimetry, pharmacokinetics, and preliminary diagnostic efficacy of HRS-6213.
- Trial name
- NCT07070349
- Testing
- HRS-6213
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Solid Tumor
A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects
This study will evaluate the safety, tolerability and pharmacokinetics of 7HP349, an allosteric integrin activator, in healthy male subjects
- Trial name
- NCT04508179
- Testing
- 7HP349 Single Ascending Dose, 7HP349 Multiple Ascending Dose, 7HP349 Food Effect
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- 7 Hills Pharma, LLC
Neoplasm Malignant
Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors
Primary Objective: To evaluate tolerability and safety of SAR408701 when administered as a single agent according to the investigational medicinal product (IMP) related dose limiting toxicities (DLTs) to determine the recommended…
- Trial name
- NCT03324113
- Testing
- SAR408701, dexamethasone, naphazoline
- Where
- 3 sites in Japan
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sanofi
Solid Tumor
A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK
AB-106-C110 is China-only study, for investigating the drug interaction between AB-106 and CYP3A4 inhibitor (Itraconazole)/CYP3A4 inducer (Rifampin)（n=56）
- Trial name
- NCT05357820
- Testing
- AB-106, Itraconazole, AB-106, Rifampicin
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Nuvation Bio Inc.
Advanced Solid Tumor
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary clinical efficacy of HY05350 for injection in patients with MSLN-positive advanced…
- Trial name
- NCT07083323
- Testing
- HY05350 for injection
- Where
- China
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Solid Tumor
Technetium [99mTc]-H7ND in Patients With Gastrointestinal Malignancies and Healthy Volunteers
The primary objective of this study is: to evaluate the safety of technetium [99mTc]-H7ND injection in patients with gastrointestinal malignancies and in healthy subjects.
- Trial name
- NCT06443710
- Testing
- Technetium [99mTc]-H7ND injection
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.
Advanced Melanoma and Normal or Impaired, Advanced Melanoma
AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
This study is a first-in-human, open-label, nonrandomized, single center Phase 1 dose-escalation study to assess the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of AB821…
- Trial name
- Asher-BioAB821 (NCT07027488)
- Testing
- AB821
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Yale University